Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)

Clinical trial NCT00760877 · COMPLETED

Trial details

NCT number

NCT00760877

Sponsor

Novartis Pharmaceuticals

Status

COMPLETED

Phase

Phase 3

Study type

INTERVENTIONAL

Start date

2009-06-01

Primary completion

2015-07-01

Enrollment

207

View on ClinicalTrials.gov